Tag - Ross Osborn

Markets

Cantor resumes coverage of Nano-X Imaging at OW; PT $21

Cantor Fitzgerald resumed coverage of Nano-X Imaging (NASDAQ:NNOX) with an “overweight” rating and 12-month price target of $21 after attending the company’s ARC Day in Israel. The stock closed at $7.60 on Jan. 4. The...

January 5, 2023

Markets

Cantor starts Mainz Biomed at OW; PT $15

Cantor Fitzgerald launched coverage of Mainz Biomed B.V. (NASDAQ:MYNZ) with an “overweight” rating and 12-month price target of $15. The stock closed at $6.63 on Oct. 24. MYNZ develops market-ready molecular genetic...

October 25, 2022

Markets

Cantor starts Asensus Surgical at OW; PT $1.50

Cantor Fitzgerald initiated coverage of Asensus Surgical (NYSE American:ASXC) with an “overweight” rating and price target of $1.50. The stock closed at 53 cents on Sept. 7. Asensus is a robotic-assisted surgery company...

September 8, 2022

Markets

Cantor assumes coverage of SI-BONE at OW; PT $34 down from $41

Cantor Fitzgerald analyst Ross Osborn assumed coverage of SI-BONE (NASDAQ:SIBN) with an “overweight” rating and price target of $34. The stock closed at $21.28 April 6. SI-BONE is a medical device company that...

April 7, 2022

Tag - Ross Osborn

Cantor resumes coverage of Nano-X Imaging at OW; PT $21

Cantor starts Mainz Biomed at OW; PT $15

Cantor starts Asensus Surgical at OW; PT $1.50

Cantor assumes coverage of SI-BONE at OW; PT $34 down from $41

General

More